Yescarta therapy

Ended Purchase Order Awarded Last action

Contract number
36C25922P1322
Awardee
Awarding agency
Obligated
$287,923

Award facts

Opportunity
  • 36C25922Q1322 Solicitation number
Contract value 100% obligated
$287,923.29 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Not Competed · 1 offer Only One Source
Pricing
Firm Fixed Price
Place of performance
Dublin, OH 43017, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00001 -$287,923
Original award $575,847

About this award

The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 19 (VA-VHA) awarded a $287,923.29 purchase order contract to Cardinal Health, Inc. for YESCARTA Therapy. As the prime contractor, Cardinal Health Inc. Division - doing business as Cardinal Health, will provide YESCARTA Therapy from August 18, 2022 through February 28, 2023 in Dublin, Ohio under firm fixed pricing terms. YESCARTA is a chimeric antigen receptor (CAR) T-cell immunotherapy manufactured by Kite Pharma, Inc., a subsidiary of Gilead Sciences, Inc., for the treatment of certain types of non-Hodgkin lymphoma. Cardinal Health will likely serve as a distributor for this therapy without conducting research and development activities itself.

Quick answers

Who was awarded contract 36C25922P1322?

36C25922P1322 was awarded to Cardinal Health, Inc. by Veterans Integrated Service Network 19 (Veterans Health Administration) on August 18, 2022.

How much is contract 36C25922P1322 worth?

The government has obligated $287,923 on 36C25922P1322.

Was contract 36C25922P1322 competed?

The extent of competition for 36C25922P1322 was not competed. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award